Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NexMed Phase III Alprox-TD data

NEXM was up $1.85 (71%) to $4.45 on 5.5 million shares on Thursday on news that

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE